<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCBCB253D3DA24C5C9FD901731BAD457E" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2444 IH: To authorize the Commissioner of Food and Drugs to award grants for studying the process of continuous drug manufacturing.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 2444</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150519">May 19, 2015</action-date> 
<action-desc><sponsor name-id="G000558">Mr. Guthrie</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To authorize the Commissioner of Food and Drugs to award grants for studying the process of continuous drug manufacturing.</official-title> 
</form> 
<legis-body id="H8D1AD990F6B148059A8D7BD8D15B5B48" style="OLC"> 
<section id="HCFDC04FC72D24F8E85DD4629B9367309" section-type="section-one"><enum>1.</enum><header>Grants for studying the process of continuous drug manufacturing</header> 
<subsection id="H3522CA451A0D437BBB7737657700E256"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs may award grants to institutions of higher education and nonprofit organizations for the purpose of studying and recommending improvements to the process of continuous manufacturing of drugs and biological products and similar innovative monitoring and control techniques.</text></subsection> <subsection id="H66FA95DCB086485A976BC456879B6D2C"><enum>(b)</enum><header>Definitions</header><text>In this section:</text> 
<paragraph id="H46103CFBAA974D0EAE3C789E863561C3"><enum>(1)</enum><text>The term <quote>drug</quote> has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text></paragraph> <paragraph id="HC8449221FD2842DC84CA63E467BB9739"><enum>(2)</enum><text>The term <quote>biological product</quote> has the meaning given to such term in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>).</text></paragraph> 
<paragraph id="H761E7C9C236F4CE585D3589391CE9C3B"><enum>(3)</enum><text>The term <quote>institution of higher education</quote> has the meaning given to such term in section 101 of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>). </text></paragraph></subsection> <subsection id="H7B8D7735D8A44FA4BE69A2638AF43576"><enum>(c)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated $5,000,000 for each of fiscal years 2016 through 2020 to carry out this section.</text></subsection></section> 
</legis-body> 
</bill> 

